Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
161.50
-4.10 (-2.48%)
Nov 15, 2024, 9:30 AM HKT
86.71%
Market Cap 35.99B
Revenue (ttm) 2.02B
Net Income (ttm) -200.51M
Shares Out 222.84M
EPS (ttm) -0.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 396,511
Open 164.30
Previous Close 165.60
Day's Range 160.60 - 177.20
52-Week Range 63.65 - 223.80
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Nov 19, 2024

About Sichuan Kelun-Biotech Biopharmaceutical

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs to address unmet medical needs in the People’s Republic of China and internationally. The company is developing various drugs to treat breast, non-small cell lung, and gastrointestinal cancer, as well as non-oncology diseases. Its product pipeline includes oncology drug candidates, such as SKB264 (sacituzumab tirumotecan), A166 (trastuzumab botidotin), SKB315, A167 (tagitanl... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Employees 1,477
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6990
Full Company Profile

Financial Performance

In 2023, Sichuan Kelun-Biotech Biopharmaceutical's revenue was 1.54 billion, an increase of 91.62% compared to the previous year's 803.93 million. Losses were -522.21 million, -4.72% less than in 2022.

Financial numbers in CNY Financial Statements

News

There is no news available yet.